U300 insulin refers to a type of insulin formulation that is 300 units per milliliter (U300) in concentration, compared with the more common 100‑unit‑per‑milliliter (U100) preparations. The “U300” label appears on a handful of basal and rapid‑acting insulins, such as:
| Brand | Type | U300 |
|-------|------|------|
| NovoLog U300 (Insulin Glargine) | Long‑acting basal | ✅ |
| Lantus U300 (Insulin Glargine) | Long‑acting basal | ✅ |
| Toujeo U300 (Insulin Glargine) | Long‑acting basal | ✅ |
| Tresiba U300 (Insulin Degludec) | Long‑acting basal | ✅ |
| Apidra U300 (Insulin Aspart) | Rapid‑acting | ✅ |
| Humalog U300 (Insulin Lispro) | Rapid‑acting | ✅ |
(There may be additional generic equivalents, but the above are the most common.)
---
Why use U300 instead of U100?
| Feature | U100 (standard concentration) | U300 (high concentration) |
|---------|------------------------------|--------------------------|
| Volume per dose | Larger volume (e.g., 0.33 mL for 33 units) | Smaller volume (e.g., 0.11 mL for 33 units) |
| Needle length | Usually 4 mm or 5 mm | 4 mm often suffices because the dose is smaller in volume |
| Injection site | Can cause more irritation/absorption variability when the needle is too long for the skin thickness | Lower risk of intramuscular injection, more consistent subcutaneous absorption |
| Dosing flexibility | Standard dose increments (e.g., 1 U, 5 U) | Allows finer dosing increments (e.g., 0.33 U, 1 U) because a single unit is a smaller volume |
| Duration of action | 24 h for glargine, ~4 h for aspart/lispro | 24 h for glargine/degludec; up to 30 h for degludec; same rapid‑acting profile for aspart/lispro |
| Storage | Same as U100 | Same as U100 (cold chain required) |
| Insurance/Cost | Often cheaper per unit | May be more expensive per unit, but fewer injections per day may offset costs |
Key take‑away: U300 offers a more concentrated insulin that delivers the same amount of insulin with a smaller injection volume. This can improve patient comfort, reduce needle‑related complications, and provide more precise dosing, especially for people who need very low or very high doses.
---
How the concentration changes the pharmacodynamics
- Basal U300 insulins (glargine and degludec) still provide a near‑constant background insulin level for 24–30 hours, but the pharmacokinetic profile is slightly flatter and lasts a bit longer due to the higher concentration and slower absorption from the subcutaneous tissue.
- Rapid‑acting U300 insulins (aspart, lispro) act as quickly as their U100 counterparts because the concentration does not change the speed of onset, only the volume delivered.
---
Practical considerations for patients
| Topic | What you should know |
|-------|----------------------|
| Needle choice | For U300, a 4 mm or 5 mm needle is usually sufficient. Check with your pharmacist or diabetes educator if you’re unsure. |
| Dosing calculations | Because the concentration is 3× higher, the dose in units is the same as U100. However, the volume in mL is one‑third of the U100 volume. Your injector or pen will usually handle the conversion automatically. |
| Switching from U100 to U300 | Most clinicians recommend starting the U300 at the same total daily dose (units) and then adjusting based on blood‑glucose monitoring. It’s not a direct 1:1 dose conversion because of individual absorption differences. |
| Side‑effects | Very similar to U100: hypoglycaemia, weight gain, local irritation. The risk of intramuscular injection is lower. |
| Insurance | Check with your plan—some cover U300; others may require prior authorization or use a generic U300 equivalent. |
---
Frequently Asked Questions
| Question | Answer |
|----------|--------|
| Is U300 insulin more expensive? | The per‑unit cost can be higher, but because you inject less volume you may use fewer injections, which can lower overall costs and improve adherence. |
| Can I use a U300 pen with a U100 insulin cartridge? | No—pens are calibrated to specific concentrations. Mixing is unsafe and may lead to dosing errors. |
| Can U300 insulin be used for both basal and bolus needs? | Yes. There are U300 basal formulations and U300 rapid‑acting formulations. Some patients use U300 basal with a U100 rapid for mealtime coverage, or both as U300, depending on their regimen. |
| Is U300 insulin suitable for children? | Yes, but the smaller volume can make accurate dosing easier for children who may have difficulty swallowing a larger syringe. |
| What about injection site pain? | Many patients report less pain because the needle must traverse a thinner subcutaneous layer. |
| Will my glucose readings differ? | The action profile is similar, but some people report slightly more stable readings due to the smoother release. |
---
Bottom line
U300 insulins are simply a more concentrated form of the same medication. They provide the same therapeutic effect with a smaller injection volume, offering advantages in dosing flexibility, reduced injection discomfort, and potentially fewer local complications. If you’re considering switching to or starting a U300 insulin, discuss it with your diabetes educator or prescribing clinician to ensure the right formulation and dosing plan for your needs.